Sign inJoin waitlistJoin the waitlist

Girish Dhall

Division Director · University of Alabama Hospital

Credentials: · · · ·

History

University of Alabama Hospital
Present
University of Alabama Hospital
Present

Pediatric Hematology Oncology
New York University
1998–2001
Neuro-Oncology-University of Southern California
1997–1998
New York Medical College
1994–1997
GRANT MED COLL, UNIV OF BOMBAY, BYCULLA, BOMBAY, INDIA
1990–1994

Research

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
The Lancet Oncology · 2019 · 409 citations
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Nature Medicine · 2005 · 376 citations
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis
Systematic review or meta-analysis · Journal of Clinical Oncology · 2010 · 227 citations

JF
Jonathan Finlay
47 papers
Ashley Margol
19 papers
JA
Jeffrey Allen
14 papers
SG
Sharon Gardner
14 papers
Maryam Fouladi
12 papers
Roger Packer
12 papers
AP
Ashok Panigrahy
11 papers
Nathan Robison
11 papers
Stewart Goldman
11 papers
Amar Gajjar
10 papers
Mark Krieger
10 papers
SK
Soumen Khatua
10 papers

Clinical trials

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Study chair · Not yet recruiting · Phase 3
Nationwide Children's Hospital
2026–2038
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Study chair · Active not recruiting · Phase 4
Parth Patel
2015–2030
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
Study director · Not yet recruiting · Phase 2
Girish Dhall, MD
2027–2032
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Study director · Not yet recruiting · Phase 2
University of Alabama at Birmingham
2026–2031